Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Exclusion Criteria

• •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Patients who have chronic conditions other than T2DM (for example, hypercholesterolemia or hypertension) but are controlled by either diet or stable (for the last 2 months) doses of medications may be included as well (for example, a subject with hypercholesterolemia on appropriate treatment is eligible).
• •Evidence or history of diabetic complications with significant end organ damage, eg, proliferative retinopathy and/or macular edema, creatinine clearance less than 60 mL/min
• •Any condition possibly affecting drug absorption (eg, gastrectomy)
• •History of stroke or transient ischemic attack or myocardial infarction within the past 6 months
• •History of coronary artery bypass graft or stent implantation.
• •Clinically significant peripheral vascular disease (eg, manifested by claudication).
• •Any history or clinical evidence of congestive heart failure, NYHA Classes II to IV.
• •One or more self reported significant/severe/requiring treatment episodes of hypoglycemia within the last 3 months, or two or more self reported significant/severe/requiring treatment episodes of hypoglycaemia within the last 6 months.
• •Current history of angina/unstable angina.
• •Milk or soy allergy